Nuvectis Pharma (NVCT) to Release Quarterly Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) will likely be releasing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Nuvectis Pharma to post earnings of ($0.26) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 7:00 AM ET.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings results on Wednesday, February 11th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.05). On average, analysts expect Nuvectis Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvectis Pharma Price Performance

NVCT opened at $8.76 on Tuesday. The firm has a market cap of $232.05 million, a PE ratio of -6.64 and a beta of -0.30. The stock has a 50-day moving average price of $8.22 and a 200-day moving average price of $6.95. Nuvectis Pharma has a 1 year low of $5.55 and a 1 year high of $11.52.

Analyst Ratings Changes

Several research analysts have issued reports on NVCT shares. HC Wainwright reaffirmed a “buy” rating on shares of Nuvectis Pharma in a report on Wednesday, December 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Nuvectis Pharma in a report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.33.

Institutional Investors Weigh In On Nuvectis Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVCT. Barclays PLC raised its stake in Nuvectis Pharma by 31.3% during the 4th quarter. Barclays PLC now owns 24,185 shares of the company’s stock valued at $183,000 after buying an additional 5,760 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Nuvectis Pharma by 15.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 44,022 shares of the company’s stock worth $332,000 after acquiring an additional 6,040 shares during the period. State Street Corp increased its position in Nuvectis Pharma by 13.1% during the fourth quarter. State Street Corp now owns 154,666 shares of the company’s stock valued at $1,168,000 after acquiring an additional 17,950 shares during the last quarter. Wells Fargo & Company MN increased its position in Nuvectis Pharma by 114.1% during the fourth quarter. Wells Fargo & Company MN now owns 16,929 shares of the company’s stock valued at $128,000 after acquiring an additional 9,022 shares during the last quarter. Finally, CIBC Private Wealth Group LLC bought a new position in Nuvectis Pharma in the fourth quarter valued at about $110,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.